Bioactives and Nanocarriers: Merging Frontiers in Cancer Therapy
Chemistry – An Asian Journal · 2025-09 · 20 (18)
DOI: 10.1002/asia.202500293 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemistry – An Asian Journal, online erschienen am 08.07.2025. Verfasst von Debolina Basu und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata, 700 032, India. Hauptthemen laut MEDLINE: Neoplasms, Drug Carriers, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: Science and Engineering Research Board, DST, India.
Abstract (Originalsprache)
In 2020, cancer was accredited for 10 million deaths, responsible for nearly one in six deaths worldwide. Nanomedicine holds significant promise for revolutionizing diagnosis and prognosis of cancer. Conventional cancer therapies including surgery, radiation therapy, and chemotherapy are chosen based on type, location, stage of cancer, and the patient's health. They typically aim to remove or control growth of cancerous cells. However, each of the therapies has its advantages, shortcomings, and side effects. To overcome this, the focus is shifting toward targeted therapy that uses bioactive molecules designed to exclusively attack cancer cells, sparing healthy ones. This approach involves engineering nanomaterials to create drug delivery systems with unique properties and functionalities. Delivering drugs via appropriate nanocarriers through surface modifications enable them to target the tumor cells. In this aspect, quantum dots, carbon nanotubes, carbon dots under inorganic nanocarriers and liposomes, dendrimers, and others belonging to organic nanocarriers are being widely used to deliver bioactives in diagnosis and treatment of cancers. This bioactive in targeted drug delivery via nanoscale miniature formulation is gaining acclaim for its potential to revolutionize cancer treatment. This review highlighted the works of various nanocarriers used as delivery vehicles that encapsulate bioactive compounds for targeted delivery to cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata, 700 032, India.
ORCID-Profile: Prasanta Kumar Das
Förderung
- Science and Engineering Research Board, DST, India
Zitieren
APA
Basu, D., Zaman, A., & Das, P. K. (2025). Bioactives and Nanocarriers: Merging Frontiers in Cancer Therapy. Chemistry – An Asian Journal, 20(18). https://doi.org/10.1002/asia.202500293
Vancouver
Basu D, Zaman A, Das PK. Bioactives and Nanocarriers: Merging Frontiers in Cancer Therapy. Chemistry – An Asian Journal. 2025;20(18). doi:10.1002/asia.202500293
BibTeX
@article{Basu2025,
author = {Basu, Debolina and Zaman, Afreen and Das, Prasanta Kumar},
title = {Bioactives and Nanocarriers: Merging Frontiers in Cancer Therapy},
journal = {Chemistry – An Asian Journal},
year = {2025},
volume = {20},
number = {18},
doi = {10.1002/asia.202500293}
}
EUVIMED